AIM ImmunoTech Company Leadership
| AIM Stock | USD 0.23 0.02 9.52% |
AIM ImmunoTech's insiders are aggressively buying. The analysis of the overall insider sentiment regarding AIM ImmunoTech suggests that most insiders are extremely bullish. AIM ImmunoTech employs about 26 people. The company is managed by 16 executives with a total tenure of roughly 55 years, averaging almost 3.0 years of service per executive, having 1.63 employees per reported executive.
AIM ImmunoTech's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-01-03 | Thomas K Equels | Acquired 161291 @ 0.31 | View |
Monitoring AIM ImmunoTech's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
AIM |
AIM ImmunoTech Management Team Effectiveness
The company has Return on Asset of (0.8004) % which means that on every $100 spent on assets, it lost $0.8004. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.5479) %, meaning that it generated no profit with money invested by stockholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to grow to -1.61. In addition to that, Return On Capital Employed is likely to grow to -2.83. At this time, AIM ImmunoTech's Total Assets are very stable compared to the past year. As of the 2nd of December 2024, Non Current Assets Total is likely to grow to about 8.5 M, while Intangible Assets are likely to drop about 1.3 M.As of the 2nd of December 2024, Common Stock Shares Outstanding is likely to grow to about 51 M
AIM ImmunoTech Workforce Comparison
AIM ImmunoTech is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 736. AIM ImmunoTech holds roughly 26.0 in number of employees claiming about 4% of equities under Health Care industry.
AIM ImmunoTech Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AIM ImmunoTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on AIM ImmunoTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AIM ImmunoTech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AIM ImmunoTech Notable Stakeholders
An AIM ImmunoTech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AIM ImmunoTech often face trade-offs trying to please all of them. AIM ImmunoTech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AIM ImmunoTech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Thomas Equels | Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel | Profile | |
| Ellen Lintal | Chief Financial Officer | Profile | |
| Jodie Pelz | Director Finance | Profile | |
| Wayne Springate | Senior Vice President - Operations | Profile | |
| III Esq | Exec COO | Profile | |
| Ann Coverly | Director Coordinator | Profile | |
| MBA IV | Chief Officer | Profile | |
| Stewart Appelrouth | Director | Profile | |
| Christopher McAleer | Scientific Officer | Profile | |
| Esq JD | CEO Chairman | Profile | |
| David Strayer | Chief Scientific & Medical Officer | Profile | |
| William Mitchell | Chairman of the Board | Profile | |
| Peter Rodino | Executive Director - Governmental Relations, General Counsel | Profile | |
| David MD | Chief Director | Profile | |
| Ralph Cavalli | Vice Manufacturing | Profile | |
| Carol Smith | Chief Officer | Profile |
About AIM ImmunoTech Management Performance
The success or failure of an entity such as AIM ImmunoTech often depends on how effective the management is. AIM ImmunoTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AIM management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AIM management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.70) | (1.61) | |
| Return On Capital Employed | (2.97) | (2.83) | |
| Return On Assets | (1.49) | (1.42) | |
| Return On Equity | (2.83) | (2.69) |
AIM ImmunoTech Workforce Analysis
Traditionally, organizations such as AIM ImmunoTech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AIM ImmunoTech within its industry.AIM ImmunoTech Manpower Efficiency
Return on AIM ImmunoTech Manpower
| Revenue Per Employee | 7.8K | |
| Revenue Per Executive | 12.6K | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 2.2M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.